SCHEMBL324429

SCHEMBL324429

Cc1cccc(C)c1COC(=O)N1C=Cc2ccccc2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.36
PPARG P37231 2/20 0.34
PPARA Q07869 2/20 0.34
P2RX4 Q99571 3/20 0.34
HSD17B3 P37058 1/20 0.33
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NOTUM Q6P988 1/20 0.32
ALDH1A1 P00352 3/20 0.32
MAPT P10636 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
XIAP P98170 1/20 0.32
KDM4E B2RXH2 1/20 0.32
SLC22A12 Q96S37 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323497 0.90 HSD17B3 (0.37) HDAC3P2RX4HSD17B3MEN1KMT2A
SCHEMBL324798 0.88 GRIN2B (0.40) HDAC3P2RX4HSD17B3MEN1KMT2A
SCHEMBL322945 0.87 ALDH1A1 (0.35) HDAC3P2RX4HSD17B3ALDH1A1MAPT
SCHEMBL323819 0.86 MMP1 (0.39) HDAC3P2RX4MEN1KMT2AALDH1A1
SCHEMBL323741 0.85 GABRA1 (0.36) HDAC3MEN1KMT2AALDH1A1MAPT
SCHEMBL15056964 0.85 HDAC3 (0.41) HDAC3HSD17B3MEN1KMT2AALDH1A1
SCHEMBL29493251 0.85 HDAC3 (0.41) HDAC3HSD17B3MEN1KMT2AALDH1A1
SCHEMBL324646 0.85 HSD17B3 (0.38) HDAC3P2RX4HSD17B3MEN1KMT2A
SCHEMBL324346 0.84 P2RX4 (0.47) P2RX4TMEM97SIGMAR1MEN1KMT2A
SCHEMBL324589 0.82 GRIN2B (0.41) P2RX4HSD17B3TMEM97SIGMAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 HDAC3 2109/4885PPARG 49/4885PPARA 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.